The use of botulinum neurotoxin (BoNT-A) for suppression of neurogenic detrusor overactivity was first reported in 2000.
Since that time, this method has gained widespread use. A number of recommendations and consensus statements have already been published. The current practice-oriented consensus paper takes into account recent developments and the over 10-year experience of most members of the Working Group Neuro-Urology of the German-speaking Medical Society for Paraplegia (DMGP) with a focus on the use of BoNT-A in paraplegic patients and in patients with multiple sclerosis.
Written by:
Böthig R, Kaufmann A, Bremer J, Pannek J, Domurath B. Are you the author?
Abteilung Neuro-Urologie, Querschnittgelähmtenzentrum, Berufsgenossenschaftliches Unfallkrankenhaus Hamburg, Bergedorfer Straße 10, 21033, Hamburg, Deutschland.
Reference: Urologe A. 2014 Apr;53(4):524-30.
doi: 10.1007/s00120-013-3419-7
PubMed Abstract
PMID: 24604016
Article in German.
UroToday.com Overactive Bladder (OAB) Section
